Introduction
============

Provirus integration site for Moloney murine leukemia virus 1 (Pim1) is one of the serine/threonine kinases. High Pim1 expression is tightly associated with clinical progression of many human cancers.[@b1-ott-12-1137]--[@b4-ott-12-1137] To date, Pim1 functions in cell proliferation, migration, apoptosis, cell cycle progression, epithelial--mesenchymal transition (EMT) and synergizes with other chemotherapeutic agents in cancers.[@b5-ott-12-1137]--[@b7-ott-12-1137] Thus, Pim1 is reported as a novel and potential target for cancer therapy. Increasing data indicate novel Pim1 specific inhibitors may be of interest in cancer therapy.[@b8-ott-12-1137]--[@b10-ott-12-1137] To further clarify the role and mechanism of Pim1 in human cancers could be beneficial for promoting the translation of Pim1 target for cancer treatment.

Nasopharyngeal carcinoma (NPC) is a kind of regional malignant cancer that is common in Southern China, Southeast Asia and northern Africa. Due to tobacco control, changes in diets and economic development and advancements in diagnostic and radiotherapy techniques, the global trends in incidence and mortality have declined.[@b11-ott-12-1137] Genetic susceptibility, and dietary and environmental factors such as Epstein--Barr virus (EBV) infection, are common causes of NPC.[@b12-ott-12-1137] The present authors' laboratory previously proved that many signaling abruptions were involved in the progression of NPC.[@b13-ott-12-1137]--[@b16-ott-12-1137] These findings expand our insights into the pathogenesis of NPC. We also have explored the biological role of Pim1 in NPC and found that high expression of Pim1 contributes to the proliferation and migration of NPC cells,[@b17-ott-12-1137] but we failed to clarify the mechanism of elevated Pim1 expression in NPC.

NPC is an EBV-associated carcinoma, and EBV-encoded LMP1 has been known to have oncogenic properties during type II latent infection in NPC.[@b18-ott-12-1137] In this study, we hypothesized that LMP1 in NPC cells may regulate Pim1 expression through certain signaling pathways and then participate in NPC progression.

Materials and methods
=====================

Patients and ethical statement
------------------------------

Paraffin-embedded specimens were obtained from 104 patients at the Affiliated Gaozhou Hospital of Guangdong Medical University during 2008--2010. Patients had not received any preoperative radiotherapy or chemotherapy. Cases included NPC (n=89; 53 male and 36 female, with a median age of 44 years) and nasopharyngeal chronic inflammation (NPI) (n=15; 10 male and five female, with a median age of 46 years). Clinical data of the NPC patients were reviewed based on the pathological tumor-node-metastasis system (AJCC/UICC 2002). All NPC patients were diagnosed with non-keratinizing carcinoma following histological examination. The use of human tissue samples in this study was approved by the Ethics Council of the Affiliated Gaozhou Hospital of the Guangdong Medical University (Gaozhou, China) for Approval of Research Involving Human Subjects. Written informed consent was obtained from the patients whose tissue specimens were used for this research, and ethical guidelines under the Declaration of Helsinki were followed.

Immunohistochemistry
--------------------

Immunohistochemistry was performed to test Pim1 protein expression in human NPC specimens by standard protocols as described previously.[@b15-ott-12-1137],[@b16-ott-12-1137] Primary antibody for Pim1 was purchased from Cell Signaling (Danvers, MA, USA; 1:50 in dilution). PBS substituted for Pim1 antibody was used as a blank control. Antigenic sites were visualized using PV9000 and DAB kits (Zhongsan Golden Bridge Biotech, Beijing, China). The immunoreactive score (IRS) of Pim1 was calculated as follows: 0, negative; 1, weak; 2, moderate; 3, strong. The percentage of positive cells was scored as 0, no positive cells; 1, 1--10% positive cells; 2, 11--50% positive cells and 3, \>51% positive cells. Samples with a total IRS of 0--1 and ≥2 were considered to be (-) and (+) of Pim1 expression.

Cell culture
------------

Well-differentiated human NPC cell line CNE1 (EBV-, presented by the Cancer Institute of Southern Medical University and its use ethically approved by Guangdong Medical University) was maintained in RPMI-1640 medium (HyClone, Beijing, China) supplemented with 10% FBS (HyClone), 100 U/mL penicillin and 100 µg/mL streptomycin. Cells were cultured at 37°C in a humidified atmosphere with 5% CO~2~. The medium was changed every 2 days. Cells in the logarithmic growth phase were used in related experiments.

Establishment and identification of LMP1 stable expression cell line
--------------------------------------------------------------------

LMP1 (GenBank: X58140.1) overexpressing lentiviruses were designed and packaged by GeneCopeia (Guangzhou, China). This LMP1 overexpressing lentiviral vectors and negative control (NC) vectors were constructed based on lentiviral vector p-EZ-Lv201 (CMV-ORF-SV40-eGFP-IRES-Puro). CNE1 cells were seeded in 6-well plates overnight, and LMP1 stably expressed and NC lentiviral particles were added at the multiplicity of infection (MOI) of 20. After infection, the cells were cultured in an incubator at 37°C, 5% CO~2~, and saturated humidity. 12 hours later, complete medium was added allowing cell growth. Medium was changed every 48 hours. At 72 hours post infection, eGFP signals were observed under fluorescence microscope to judge the transfection efficiency. Then cells were screened with 2.0 µg/mL puromycin (Sigma-Aldrich Co., St Louis, MO, USA), and immunoblot was performed to determinate the expression of LMP1.

Drug treatment and grouping
---------------------------

To explore the mechanisms regarding LMP1 mediates Pim1 expression, we treated CNE1-LMP1-OV cells with inhibitors of LMP1 downstream signals. Cells were grouped into dimethyl sulfoxide (DMSO) (complete medium containing 0.1% DMSO, v/v), pyrrolidine dithiocarbamate (PDTC) (complete medium supplemented with 10 µmol/L NF-κB inhibitor, Beyotime Institute of Biotechnology, Haimen, China), GF109203X (complete medium supplemented with 10 µmol/L PKC inhibitor, Selleck, Houston, TX, USA), Stattic (complete medium supplemented with 10 µmol/L STAT3 inhibitor, Selleck) and SR11302 (complete medium supplemented with 10 µmol/L AP-1 inhibitor, ApexBio, Houston, TX, USA). Total protein was extracted after 48 hours, and the expression of Pim1 was detected by immunoblot. In order to clarify the effects of suppression of Pim1 activity on cell proliferation, CNE1-LMP1-OV cells were treated with Pim1 inhibitor quercetagetin[@b19-ott-12-1137] (Cal Chemical Corp., Coventry, RI, USA), details were included in the following cell counting kit-8 (CCK-8) assay and plate clone formation assay.

RNA isolation, RT and quantitative PCR
--------------------------------------

Total RNA from cells were extracted with Trizol (Ambion, Foster City, CA, USA). 500 ng total RNA was used to generate cDNA using an RT kit (TaKaRa, Kusatsu, Japan) with an oligo (dT18) primer. Quantitative PCR was conducted using a Light-Cycler480 II instrument (Roche China, Guangzhou, China) as described previously.[@b13-ott-12-1137],[@b20-ott-12-1137] Primers (5′--3′) were synthesized by Sangon Biotech (Shanghai, China) as follows: Pim1 (NM_002648.3), 5′-CTTCGGCTCGGTCTACTCAG-3′, 5′-AGTGCCATTAGGCAGCTCTC-3 ′; β-actin (BC002409), 5′-TGACGTGGACATCCGCAAAG-3′, 5′-CTGGAAGGTGGACAGCGAGG-3′. The 20 µL PCR reaction system consisted of 10 µL of mixture containing SYBR, 2 µL of cDNA, 1.6 µL of upstream and downstream primers and 6.4 µL of d~2~H~2~O. For PCR analyses, the expression of β-actin served as a loading control. The PCR cycle parameters were performing pre-denaturation at 95°C for 5 minutes, followed by 45 cycles at 95°C for 10 seconds and 60°C for 30 seconds. The 2^−ΔΔCt^ method was used to determine the levels of target gene expression.

Immunoblot
----------

Immunoblot was performed as previously described.[@b20-ott-12-1137] A total of 50 µg of protein was transferred onto PVDF membranes by electrophoretic transfer following electrophoretic separation by 12% SDS-PAGE. The antibodies used were rabbit-anti human Pim1 (1:1,000; Cell Signaling), rabbit-anti human PCNA (1:1,000; Cell Signaling), mouse-anti LMP1 (1:500; Abcam, Cambridge, UK) and rabbit-anti human β-actin (1:3,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The membranes were incubated overnight at 4°C, washed with tris-buffered saline-Tween (TBST), and incubated with HRP-labeled IgG (1:3,000; ProteinTech, Wuhan, China) for 2 hours at room temperature. After ECL luminescence, the target protein bands were scanned with gel imaging system (Tanon, Shanghai, China).

Immunofluorescence staining
---------------------------

Cells grown on coverslips and NPC specimens were subjected to indirect immunofluorescence to identify the expression and location of Pim1, PCNA and LMP1, which was performed as described previously.[@b21-ott-12-1137] Images were captured using a laser scanning confocal microscope (TCS SP5 II; Leica Micro-systems, Wetzlar, Germany). For the antigen localization, fluorescein isothiocyanate (FITC)- or tetramethylrhodamine isothiocyanate (TRITC)-coupled IgGs (ProteinTech, Wuhan, China) were used. Nuclei were count stained with DAPI (Sigma-Aldrich).

Cell viability assessed by CCK-8 assay
--------------------------------------

Proliferation rates were determined using CCK-8 assays as described previously.[@b16-ott-12-1137] Briefly, CNE1-LMP1-OV cells and CNE1-eGFP cells were seeded in 96-well plates (3,000 cells/per well), cells were treated with DMSO (0.1%, v/v) or 5.5 µmol/L quercetagetin for either 0, 24 or 48 hours, then a 100 µL mixture of CCK-8 reagent (Cat. \#C0038, Beyotime Institute of Biotechnology) and RPMI-1640 (v/v=1/10) was added per well. Three hours later, the optical density was measured using a microplate reader (Multiskan MKS, Thermo Fisher Scientific, Waltham, MA, USA) in dual wavelength mode (450/630 nm). Each group was repeated in 6 wells, and data are presented as mean ± SEM of 3 independent experiments.

Plate clone formation assay
---------------------------

CNE1-LMP1-OV cells were seeded onto 6-well plates with 500 cells/well. After one night recovery, cells were administrated with medium enriched in DMSO (0.1%, v/v) and quercetagetin (5.5 µmol/L). The medium was changed every two days; 10 days later, PBS-washed cells were fixed with 4% formalin following stained with 0.1% crystal violet. The clone formation efficiency was calculated. Each group was repeated in 3 wells.

Statistical analysis
--------------------

Statistical analyses were conducted using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA). Correlation analysis of Pim1 expression and related parameters in clinical specimens was performed using the chi-squared test. In vivo experimental data are expressed as mean ± SEM. Differences between two groups were analyzed using Student's *t*-test. For comparisons between multiple groups, ANOVAs were used followed by the Student--Newman--Keuls test. *P*\<0.05 was considered to be statistically significant.

Results
=======

Immunohistochemical results and correlation analysis in clinical specimens
--------------------------------------------------------------------------

Among 89 cases of NPC, 48 cases (53.93%) were Pim1 positive, while only one case (6.67%, 1/15) was Pim1 positive in NPI (*P*\<0.001). Further hierarchical studies showed that positive expression of Pim1 was not associated with age, gender, smoking condition or clinical classification of NPC patients, but was positively correlated with T classification, N classification and M classification (all *P*\<0.05). Regarding the intracellular localization, we found Pim1 protein was expressed in both nucleus and cytoplasm and mainly expressed in the nucleus. We selected some samples for immunofluorescence qualitative and localization detection, and found that the tumor area in the clinical NPC samples showed obvious nucleus positive for Pim1, while it was absent in epithelial cells in the control groups ([Figure 1](#f1-ott-12-1137){ref-type="fig"}, [Table 1](#t1-ott-12-1137){ref-type="table"}).

Establishment of LMP1 stably overexpressing NPC cell line
---------------------------------------------------------

Given that NPC is an EBV-associated cancer, we hypothesized that EBV infection may mediate Pim1 expression through its encoded LMP1. To this end, we infected LMP1 overexpressing lentivirus and NC lentivirus into CNE1 cells, respectively, and obtained stable expression cell lines by puromycin stress. As results, the eGFP signal generated by lentivirus-infected CNE1 cells was observed under fluorescence microscopy ([Figure 2A](#f2-ott-12-1137){ref-type="fig"}). Further immunofluorescence ([Figure 2B](#f2-ott-12-1137){ref-type="fig"}) and immunoblot results ([Figure 2C and D](#f2-ott-12-1137){ref-type="fig"}) confirmed the successful detection of LMP1 in the experimental group. Thus, this successful establishment of LMP1-overexpressing cell line laid a foundation for further analysis of the effects and mechanisms of LMP1-regulated Pim1 expression.

LMP1 promotes proliferation of NPC cells
----------------------------------------

LMP1 has functions such as promoting cell proliferation, inhibiting apoptosis and inducing EMT in cells. As shown in [Figure 3](#f3-ott-12-1137){ref-type="fig"}, by immunofluorescence and immunoblot, we confirmed that overexpression of LMP1 significantly induced the expression of PCNA, the marker for cell proliferation, in NPC cells. The immunofluorescence signal indicated that the expression of PCNA in the highly differentiated CNE1 cells before LMP1 transfection was weak and mostly cytoplasmic expression, while the expression of PCNA was enhanced after LMP1 infection and the nuclear localization was dominant.

LMP1-induced Pim1 expression mediates NPC cell proliferation
------------------------------------------------------------

Based on the successful construction of LMP1 stably expressing cells, we further analyzed the effect of LMP1 on Pim1 expression. The results confirmed that LMP1 positively regulates Pim1 expression at both transcriptional and translational levels ([Figure 4A--C](#f4-ott-12-1137){ref-type="fig"}). The Pim1 gene expresses two proteins, namely a larger 44 kDa protein and a smaller 33 kDa one, due to its two selective stop codons.[@b22-ott-12-1137] We first found that LMP1 in NPC mainly induced the expression of the 33 kDa small Pim1 protein ([Figure 4B](#f4-ott-12-1137){ref-type="fig"}). Subsequently, the LMP1 stably expressed CNE1 cells and control cells were treated with Pim1 specific activity inhibitor quer-cetagetin,[@b17-ott-12-1137] and we found that suppression of Pim1 activity by quercetagetin significantly attenuated the proliferative activity of LMP1-expressing cells but not the control cells ([Figure 4D and E](#f4-ott-12-1137){ref-type="fig"}).

The mechanism of LMP1 inducing Pim1 expression
----------------------------------------------

LMP1 stably expressed CNE1 cells were treated with classical inhibitors of LMP1 downstream signaling including NF-κB, PKC, STAT3 and AP-1, respectively. Quantitative PCR and immunoblot results confirmed that compared with DMSO control groups, NF-κB inhibitors PDTC and PKC inhibitor GF109203X significantly attenuated the expression of Pim1, and the STAT3 inhibitor Stattic attenuated the expression of Pim1 to a certain extent, while the AP-1 inhibitor SR11302 had no effects on the expression of Pim1 in NPC cells ([Figure 5](#f5-ott-12-1137){ref-type="fig"}). Details of the mechanisms of LMP1-induced Pim1 expression in NPC cells are summarized in [Figure 6](#f6-ott-12-1137){ref-type="fig"}.

Discussion
==========

We have previously reported that Pim1 is differentially expressed in various differentiation statuses of NPC cell lines, and inhibition of Pim1 by quercetagetin significantly attenuated high Pim1-expressing cell proliferation.[@b17-ott-12-1137] In this study, we aimed to further clarify the role of Pim1 in clinical NPC progression and its mediated mechanism. To this end, through analysis of Pim1 protein expression in clinical NPC specimens, we found that Pim1 expression rate was significantly higher than that in control NPI specimens, suggesting a positive role of Pim1 in NPC biology. Subsequently, we found that Pim1 expression was positively related to NPC patients' T classification, N classification and M classification, which further indicated overexpression of Pim1 contributes to NPC clinical progression. Regarding Pim1 expression in cancers, increasing data have proved that high Pim1 expression plays a pivotal role in progression of cancers including hematological malignancy,[@b4-ott-12-1137],[@b23-ott-12-1137] epithelial cell-derived tumors[@b1-ott-12-1137],[@b2-ott-12-1137],[@b7-ott-12-1137] and mesenchymal neoplasms.[@b24-ott-12-1137],[@b25-ott-12-1137] Our current investigation provides additional evidence about Pim1 expression in NPC, a head and neck tumor with unique regional and ethnic distribution differences.

As mentioned above, NPC is an EBV-associated malignancy. During the process of latent infection, three EBV-encoded proteins, namely Epstein--Barr nuclear antigen 1 (EBNA1), LMP1 and LMP2 were expressed, while LMP1 is deemed to be the central player in the development of NPC.[@b26-ott-12-1137] Therefore, LMP1 reserves therapeutic interests in NPC.[@b27-ott-12-1137],[@b28-ott-12-1137] Based on this background, we tried to clarify whether the LMP1/Pim1 signal axis exists in the NPC. Thus, we generated LMP1 stably-expressing CNE1 cell line by infecting the EBV negative, well-differentiated CNE1 cells. Initial results indicated this cell line was successfully established, and forced expression of exogenous LMP1 led to significantly Pim1 upregulation both at the transcriptional and translational levels. This causal relationship suggests the presence of the LMP1/Pim1 signal axis in the NPC.

How does LMP1 mediate Pim1 expression in NPC? To answer this question, we adopted various inhibitors for LMP1 downstream signals, including NF-κB, PKC, Jak/STAT3 and AP-1.[@b29-ott-12-1137] The results showed that NF-κB inhibitor PDTC, PKC inhibitor GF109203X and STAT3 inhibitor Stattic displayed significantly suppressive effects, while AP-1 inhibitor SR11302 showed no effects on Pim1 expression. Thus, LMP1 may mediate Pim1 expression in NPC cells, mainly through NF-κB, PKC and Jak/STAT3 signaling. The mechanisms were illustrated in [Figure 6](#f6-ott-12-1137){ref-type="fig"}. This finding broadens our insights on molecular mechanisms about LMP1 in NPC carcinogenesis.

As illustrated by the relationship between Pim1 expression and NPC patient's clinical parameters, Pim1 expression showed no association with NPC patients' age, gender, smoking status and clinical classification; however, it was positively related to NPC patients' T, N and M classification. These epidemiological correlation analysis results indicated that Pim1 expression plays a critical role in NPC clinical progression due to cell proliferation and metastasis. We currently focused on cell proliferation. Consistent with our expectations, we found that LMP1-induced increase in Pim1 expression indeed promoted proliferation of NPC cells. Our results were consistent with other lab findings that proved high Pim1 expression enhanced cancerous cell growth.[@b1-ott-12-1137],[@b30-ott-12-1137]--[@b32-ott-12-1137]

So far, Pim1 has attracted much interest in cancer target therapy. Many new generations of Pim1 inhibitors have been designed and tested.[@b8-ott-12-1137],[@b9-ott-12-1137] Flavonol quercetagetin (3,3′,4′,5,6,7-hydroxyflavone) was a moderately potent and selective inhibitor of Pim1 kinase.[@b19-ott-12-1137] The mechanism of quercetagetin anti-Pim1 is due to the suppression of Pim1 activity but not its expression, which could be assessed by the changes in downstream gene expression or phosphorylation modification state.[@b19-ott-12-1137],[@b20-ott-12-1137],[@b33-ott-12-1137] Our previous report[@b17-ott-12-1137] and another laboratory[@b33-ott-12-1137] proved that quercetagetin effectively inhibited cell proliferation. Future investigations using novel and selective Pim1 inhibitors would strengthen the basis for clinical application of Pim1 inhibitors in NPC adjuvant therapy.

Some limitations exist in this study. 1) Due to the low detectability of LMP1 protein in clinical NPC samples, we have not successfully shown the relation of Pim1 to LMP1 in clinical NPC specimens. 2) We only focused on cell proliferation in this study; other cell biological functions such as apoptosis, migration should be considered. 3) The current change in phenotypes of Pim1-induced cells was based on overexpression of LMP1 through the CNE1-LMP1-OV cell line, which could potentially give rise to phenotypes that are not biologically relevant. Therefore, it is more convincing to test LMP1-positive cells from tumor tissues of clinical NPC patients. 4) In vivo animal experiments would make our current conclusion more solid.

Conclusion
==========

High Pim1 expression was positively related to NPC patients' clinical progression, and LMP1 mediated Pim1 mainly through NF-κB, PKC and STAT3 signaling. This LMP1-induced cell proliferation could be attenuated by the Pim1 inhibitor. Our current study provided novel mechanism of LMP1-mediated NPC cell progression and supported Pim1 as a potential target in NPC treatment.
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![Pim1 was upregulated in NPC clinical specimens.\
**Notes:** (**A**) Pim1 immunohistochemistry. Representative images of Pim1 expression in clinical specimens. PBS substituted for primary antibody was served as blank control, nuclei were counterstained with hematoxylin. Bars, 100 µm. (**B**) Representative immunofluorescence images of Pim1 in NPC and NPI clinical specimens. Nuclei were counterstained with DAPI, and antigens for Pim1 were colorized with rhodamine-coupled IgGs. Bars, 50 µm.\
**Abbreviations:** DAPI, 4′,6-diamidino-2-phenylindole; NPC, nasopharyngeal carcinoma; NPI, nasopharyngeal chronic inflammation.](ott-12-1137Fig1){#f1-ott-12-1137}

![Establishment of LMP1 overexpressing cell line.\
**Notes:** (**A**) Efficiency of lentiviral infection in CNE1 cells. LMP1 overexpressing lentiviral particles and control lentiviral particles infected the CNE1 cells at MOI of 20, 3 days post infection, and the eGFP signal was observed under a fluorescence microscope. Bars, 200 µm. (**B**) Detection of LMP1 in lentivirus-infected CNE1 cells by immunofluorescence staining. Nuclei were counterstained with DAPI, and antigens for LMP1 were colorized with FITC-coupled IgGs. Bars, 100 µm. (**C**) Immunoblotting of LMP1 protein in established cell lines. (**D**) Semiquantitative results of LMP1. The experiment was repeated three times (n=3). \*\*\**P*\<0.001.\
**Abbreviation:** DAPI, 4′,6-diamidino-2-phenylindole.](ott-12-1137Fig2){#f2-ott-12-1137}

![LMP1 induces PCNA expression in NPC cells.\
**Notes:** (**A**) Detection of PCNA in lentivirus-infected CNE1 cells by immunofluorescence staining. Nuclei were counterstained with DAPI, and antigens for PCNA were colorized with TRITC-coupled IgGs. Bars, 50 µm. (**B**) Immunoblotting of PCNA in established cell line. The experiment was repeated three times (n=3) and the representative bands are shown. \*\*\**P*\<0.001.\
**Abbreviations:** DAPI, 4′,6-diamidino-2-phenylindole; PCNA, proliferating cell nuclear antigen; TRITC, tetramethylrhodamine isothiocyanate.](ott-12-1137Fig3){#f3-ott-12-1137}

![LMP1-induced Pim1 expression promotes NPC cell proliferation.\
**Notes:** (**A**) Enhanced Pim1 mRNA levels in LMP1 stably expressing cells. \*\*\**P*\<0.001. The experiment was repeated three times (n=3). (**B**) LMP1 mainly upregulates the 33 kDa Pim1 protein but not the 44 kDa protein in NPC cells. The experiment was repeated three times (n=3) and the representative bands are shown. (**C**) Expression and cellular location of Pim1 protein in NPC cells. Antigens for Pim1 were colorized with TRITC-coupled IgGs. Bars, 75 µm. (**D**) Cell viability of LMP1-overexpressing cells and control cells treated with Pim1 inhibitor quercetagetin, assessed by CCK-8 assay. \**P*\<0.05. Each group was repeated in six wells (n=6). (**E**) Clone formation efficiency of quercetagetin-treated cells. \**P*\<0.05. Each group was repeated in three wells (n=3).\
**Abbreviations:** CCK-8, cell counting kit-8; DAPI, 4′,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; NS, no significance; TRITC, tetramethylrhodamine isothiocyanate.](ott-12-1137Fig4){#f4-ott-12-1137}

![Signaling involved in LMP1-induced Pim1 expression in NPC cells.\
**Notes:** (**A**) Pim1 mRNA levels were detected in LMP1 downstream signaling inhibitors including PDTC, GF109203X, Stattic and SR11302. \**P*\<0.05, \*\*\**P*\<0.001; PDTC, NF-κB inhibitor; GF109203X, PKC inhibitor; Stattic, STAT3 inhibitor; SR11302, AP-1 inhibitor. The experiment was repeated three times (n=3). (**B**) Pim1 protein levels were detected in LMP1 downstream signaling inhibitors including PDTC, GF109203X, Stattic and SR11302. \**P*\<0.05, \*\*\**P*\<0.001. The experiment was repeated three times (n=3) and the representative bands are shown.\
**Abbreviations:** DMSO, dimethyl sulfoxide; PDTC, pyrrolidine dithiocarbamate.](ott-12-1137Fig5){#f5-ott-12-1137}

![Schematic illustration of the mechanism of LMP1/Pim1 signaling--promoted proliferation in NPC cells.\
**Notes:** Based on results from the literature[@b29-ott-12-1137] and this study, the mechanism of LMP1-induced Pim1 expression regulating the proliferation of NPC cells is illustrated. EBV encodes transmembrane protein LMP1 in NPC cells, through its C-terminal activation regions 1, 2 and 3 (CTAR1, CTAR2 and CTAR3), LMP1 activates NF-κB, Jak/STAT3, PKC and AP1 signaling. Inhibition of NF-κB, PKC and Jak/STAT3 signaling by its specific blocker attenuates LMP1-enhanced Pim1 expression, while inhibition of AP1 shows no effect on Pim1 expression. Consequently, this upregulated Pim1 promotes NPC cell proliferation, while inhibition Pim1 activity by quercetagetin suppresses cell proliferation.\
**Abbreviations:** AP-1, activator protein 1; CTAR, C-terminal activation regions; EBV, Epstein--Barr virus; NF-κB, nuclear factor κB; NPC, nasopharyngeal carcinoma; PDTC, pyrrolidine dithiocarbamate; PKC, protein kinase C; STAT3, signal transducer and activator of transcription 3.](ott-12-1137Fig6){#f6-ott-12-1137}

###### 

The expression of Pim1 protein in clinical specimens and its correlation to NPC patients' clinical parameters

  Clinical parameters       n    Pim1   *P*-value   
  ------------------------- ---- ------ ----------- -----------------------------------------------------
  Histological type                                 
   NPC                      89   48     41          \<0.001[\*](#tfn1-ott-12-1137){ref-type="table-fn"}
   NPI                      15   1      14          
  Gender                                            
   Male                     53   29     24          0.603
   Female                   36   18     18          
  Age                                               
   ≥50                      44   24     20          0.746
   \<50                     45   23     22          
  Smoking                                           
   Yes                      38   21     17          0.689
   No                       51   26     25          
  Clinical classification                           
   I--II                    17   7      10          0.285
   III--IV                  72   40     32          
  T classification                                  
   T1--T2                   34   12     22          0.030[\*](#tfn1-ott-12-1137){ref-type="table-fn"}
   T3--T4                   55   32     23          
  N classification                                  
   N0--N1                   50   21     29          0.021[\*](#tfn1-ott-12-1137){ref-type="table-fn"}
   N2--N3                   39   27     12          
  M classification                                  
   M0                       72   34     38          0.034[\*](#tfn1-ott-12-1137){ref-type="table-fn"}
   M1                       17   13     4           

**Note:**

Significance as indicated.

**Abbreviations:** NPC, nasopharyngeal carcinoma; NPI, nasopharyngeal chronic inflammation.
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